# Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

> **NCT05267054** · PHASE1,PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 53 (actual)

## Conditions studied

- Relapsed Diffuse Large B-cell Lymphoma
- Refractory Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Ociperlimab
- **DRUG:** Tislelizumab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05267054
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-25
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05267054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05267054, "Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT05267054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*